A fascinating example of philanthropy targeting a neglected public-good problem. Intercept is a new $500M initiative backed by Stripe, Anthropic, OpenAI Foundation, Bill Gates, and others to develop broad-spectrum antivirals and improve indoor air quality, with the ambitious goal of making common respiratory infections far rarer. The article argues that colds and flu impose massive health and productivity costs but fall into a funding gap between government, philanthropy, and private markets.
It also raises an interesting question about how we prioritize philanthropic spending: $500M is a huge commitment, but how does it compare with fundraising efforts for diseases like breast cancer, which attract *billions* in donations annually? Given the enormous health and economic burden of respiratory infections, are we underinvesting in prevention, and could we be doing more to fund ambitious solutions to neglected problems?
1 Comment
A fascinating example of philanthropy targeting a neglected public-good problem. Intercept is a new $500M initiative backed by Stripe, Anthropic, OpenAI Foundation, Bill Gates, and others to develop broad-spectrum antivirals and improve indoor air quality, with the ambitious goal of making common respiratory infections far rarer. The article argues that colds and flu impose massive health and productivity costs but fall into a funding gap between government, philanthropy, and private markets.
It also raises an interesting question about how we prioritize philanthropic spending: $500M is a huge commitment, but how does it compare with fundraising efforts for diseases like breast cancer, which attract *billions* in donations annually? Given the enormous health and economic burden of respiratory infections, are we underinvesting in prevention, and could we be doing more to fund ambitious solutions to neglected problems?